MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

$54.32 +2.46 (+4.74%)

(As of 11/22/2024 ET)

MoonLake Immunotherapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
2

Buy
8

Based on 10 Wall Street analysts who have issued ratings for MoonLake Immunotherapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for MLTX.

Consensus Price Target

$79.00
45.43% Upside

According to the 10 analysts' twelve-month price targets for MoonLake Immunotherapeutics, the average price target is $79.00. The highest price target for MLTX is $104.00, while the lowest price target for MLTX is $62.00. The average price target represents a forecasted upside of 45.43% from the current price of $54.32.

Get the Latest News and Ratings for MLTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MoonLake Immunotherapeutics and its competitors.

MLTX Analyst Ratings Over Time

Type	Current Forecast 11/24/23 to 11/23/24	1 Month Ago 10/25/23 to 10/24/24	3 Months Ago 8/26/23 to 8/25/24	1 Year Ago 11/24/22 to 11/24/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	9 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$79.00	$80.45	$78.67	$67.70
Forecasted Upside	45.43% Upside	74.14% Upside	58.06% Upside	45.97% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)

If you missed out on Nvidia, watch this video I just made.

Click here for full details.

MLTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MLTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MoonLake Immunotherapeutics Stock vs. The Competition

Type	MoonLake Immunotherapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	45.43% Upside	27,098.21% Upside	7.66% Upside
News Sentiment Rating	Positive News See Recent MLTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+95.85%
11/5/2024	Wedbush 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$92.00 ➝ $73.00	+57.33%
9/23/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
9/12/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$62.00 ➝ $62.00	+33.56%
8/26/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$104.00	+168.66%
Top secret Trump trades? (Ad) As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.” Go here to see how you can start accessing these opportunities today
4/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$62.00	+27.57%
2/26/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$92.00	+76.52%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$66.00 ➝ $69.00	+14.56%
12/8/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$72.00	+30.32%
11/15/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$70.00 ➝ $77.00	+90.83%
9/14/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
9/12/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$41.00 ➝ $59.00	+12.12%
6/27/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$36.00 ➝ $68.00	+47.99%
6/26/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$28.00 ➝ $56.00	+21.87%
5/4/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
12/21/2022	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Katkhuda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:10 PM ET.

MLTX Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for MoonLake Immunotherapeutics is $79.00, with a high forecast of $104.00 and a low forecast of $62.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
: According to analysts, MoonLake Immunotherapeutics's stock has a predicted upside of 45.43% based on their 12-month stock forecasts.
: Over the previous 90 days, MoonLake Immunotherapeutics's stock had 1 upgrade and 1 downgrade by analysts.
: MoonLake Immunotherapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Wedbush, and Wolfe Research in the past 90 days.
: Analysts like MoonLake Immunotherapeutics more than other "medical" companies. The consensus rating score for MoonLake Immunotherapeutics is 2.90 while the average consensus rating score for "medical" companies is 2.80. Learn more on how MLTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)

If you missed out on Nvidia, watch this video I just made.

Click here for full details.

This page (NASDAQ:MLTX) was last updated on 11/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target